Background
==========

Sporadic cerebral amyloid angiopathy (CAA) is a common but often asymptomatic neuropathological finding, characterized by the deposition of amyloid-β (Aβ) in small and medium-sized cerebral arteries, arterioles and sometimes capillaries of the meninges and brain parenchyma. Its prevalence is strongly associated with increasing age and has been reported to be as high as 57% percent in case series of asymptomatic patients over 60 years of age \[[@B1]\]. CAA is a common finding in patients with Alzheimer\'s disease (AD); but many patients with CAA do not develop AD. CAA can lead to lobar haemorrhage in non-hypertensive patients \[[@B2]\]. Other, less often reported clinical manifestations are seizures, transient neurological deficits and dementia other than AD \[[@B3]\]. In addition, more rare presentations have been reported, including space occupying lesions and leukoencephalopathy on magnetic resonance imaging (MRI) \[[@B4]-[@B6]\]. The latter is an increasingly recognized syndrome encompassing subacute encephalopathy, headache, seizures or focal neurological symptoms. Upon brain biopsy, an inflammatory process is found in relation to the vascular deposits of Aβ. In contrast to other Aβ-depositing disorders such as AD, immunosuppressive treatment has been reported to ameliorate both clinical and radiological symptoms of CAA encephalopathy, although with variable success \[[@B7]\]. This variability could be explained by the existence of different underlying pathological subtypes. We describe a patient with CAA-leukoencephalopathy, who was treated successfully with dexamethasone. We also performed a literature review concerning the use of immunosuppressive treatment for CAA-related inflammation with special attention to its pathological subtypes.

Case presentation
=================

A 74-year-old man with an unremarkable medical history noted a progressive gait disorder in the months prior to admission. His wife recalled increased sleepiness and loss of initiative. After having seizures the patient was admitted to our hospital. The patient was disorientated in time and did not perform complicated tasks, although this could partly be attributed to apathy. He could not remember the reason for his stay in the hospital. The remaining neurological examination revealed no abnormalities. MRI showed confluent bifrontal white matter lesions and minimal enhancement of the white matter in the right frontal lobe after administration of gadolinium (Figure [1A-D](#F1){ref-type="fig"}). Routine laboratory measurements were normal. Cerebral spinal fluid examination revealed an elevated protein level (1.78 g/l). No malignant cells were found in the spinal fluid. After diagnostic work-up had excluded a primary tumour elsewhere in the body, low grade astrocytoma or gliomatosis cerebri was considered and a stereotactic brain biopsy was performed. Histopathological analysis showed extensive Aβ immunopositivity around smaller and larger blood vessels (Figure [2A, B](#F2){ref-type="fig"}). No neurofibrillary tangles or amyloid plaques were found in the parenchyma. Reactive gliosis, strong upregulation of microglia and multiple macrophages around the blood vessels in both white and grey matter were present (Figure [2C, D](#F2){ref-type="fig"}). The findings were compatible with sporadic CAA. After the patient developed progressive apathy, loss of initiative, magnetic gait and hypertonia of the extremities, treatment with dexamethasone (2 × 4 mg/day) was started. There was a remarkable clinical improvement in the following days. The patient became alert, the hypertonia disappeared and he was able to walk with a wheeled walker. After 5 weeks, he was discharged from the hospital with a mild gait disorder. A 3 Tesla MRI three months after admission showed remarkable amelioration of the white matter abnormalities. Gradient echo sequences showed subcortical hypointensities, compatible with multiple microbleeds (figure [1](#F1){ref-type="fig"}). Dexamethasone treatment was tapered in the months after admission.

![**Axial MRI at presentation (A, B) and 3 months after treatment (C, D)**. A) Contrast enhanced, T1- weighted image shows low signal intensity of the right frontal lobe with minimal enhancement of the white matter (white arrowhead). B) T2-weighted image shows high signal intensity in the right frontal lobe. C) Gradient echo sequence shows subcortical \'black dots\', consistent with microbleeds (white arrows), and a small postoperative hematoma after biopsy. D) T2-weighted image after treatment shows a decrease of high signal intensity in the right frontal lobe.](1742-2094-7-18-1){#F1}

![**Cytological and histological examination of biopsy**. A) Smear slide showing amyloid (metachromatic, purple) around a capillary (toluidin blue stain), B) paraffin-embedded material: extensive amyloid deposition around capillaries in cortex (Aβ immunoreaction), C) reactive gliosis and upregulation of microglia and macrophages in grey matter, D) reactive gliosis, upregulation of microglia and presence of macrophages in white matter (C and D, HLA-DR (CR3/43) immunoreaction).](1742-2094-7-18-2){#F2}

Discussion
==========

The clinical picture of CAA-related inflammation includes encephalopathy, seizures and headaches. Extensive vasogenic edema and/or leukoencephalopathy is visible on MRI, sometimes mimicking space-occupying lesions. Histological examination shows amyloid-laden vessels and the appearance of Aβ in close association with inflammatory cells, implicating Aβ as the potential trigger for the inflammatory response. It remains unclear why only a few CAA patients develop this response. A high percentage of such patients are homozygous for the ε4-allele of the apolipoprotein E gene (APOE ε4/ε4; 76.9% vs 5.1% in non-inflammatory CAA) \[[@B6]\], which is associated with activation of complement and microglia. Additionally, trials of anti-Aβ vaccination in patients with Alzheimer\'s disease (AD) induced similar clinical, radiological and pathological inflammation as seen in CAA-related inflammation, suggesting an immune response to Aβ.

Unlike other Aβ-depositing disorders, CAA-associated inflammation appears to derive a beneficial effect from corticosteroid treatment. This effect could be dependant on the pathological subtype of CAA-related inflammation.

Two subtypes of CAA-associated inflammation have been described so far: (i) a non-vasculitic form called perivascular infiltration (PVI), which is characterized by perivascular infiltration of the parenchyma by multinucleated giant cells and (ii) a vasculitic form called transmural (non)-granulomatous angiitis (TGA), which is characterized by inflammation of the vessel wall with the occasional presence of granulomas. Both pathologic forms can co-occur, suggesting at least a partial overlap \[[@B8]\]. The clinical and radiological findings of both variants are remarkably similar. Our case showed reactive gliosis and multiple macrophages around blood vessels in grey and white matter, although no multinucleated cells were seen. This is consistent with reactive edema in encephalopathy and suggests PVI. Although often called CAA-angiitis, the terms CAA-vasculopathy or CAA-encephalopathy are preferred, since these terms do not exclude the considerable numbers of cases with only perivascular inflammation \[[@B8]\].

Because of various reports regarding success of corticosteroid treatment, we performed a literature review on the use of immunosuppressive agents in CAA-encephalopathy with special attention to its pathological subtypes. A total of 45 patients in 18 articles could be identified (Table [1](#T1){ref-type="table"}) \[[@B4]-[@B6],[@B8]-[@B22]\]. In four patients TGI and PVI co-occurred \[[@B8],[@B15],[@B18]\]. Corticosteroids were the most commonly used drugs, varying from short, high-dosage intravenous treatments to continuous treatment with low-dose prednisone. One case report reported effective treatment with low dose cyclophosmamid alone \[[@B16]\]. Similar to our case, there were generally favourable outcomes in most patients after immunosuppressive treatment. Clinical and radiological symptoms were (partly) reversed in 76% of all patients, although some experienced relapses during follow-up.

###### 

Studies concerning immunosuppresive treatment of CAA encephalopathy

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                            n    Age         Pathology              Radiology        Therapy           Clinical improvement   Radiological improvement   Follow-up        Clinical features                               Comments
  --------------------------------- ---- ----------- ---------------------- ---------------- ----------------- ---------------------- -------------------------- ---------------- ----------------------------------------------- ------------------------------------------------------------------------------------
  Ginsberg 1988 \[[@B10]\]          1    73          TGA                    Confluent        Dx, Pn            Yes                    Yes                        \>1 year         Gait disturbance                                

                                                                                                                                                                                                                                  

  Mandybur 1992 \[[@B11]\]          1    62          TGA                    Mass             CP, Pn            Yes                    Yes                        Death 8 months   Encephalopathy Focal neurology Hallucinations   Remarkable pathological improvement lesions post-mortem compared to initial biopsy

                                                                                                                                                                                                                                  

  Osumi 1995 \[[@B4]\]              1    59          ?                      Mass             CS                No                     ?                          Death 5 months   Focal neurology\                                
                                                                                                                                                                                  Headaches\                                      
                                                                                                                                                                                  Seizures                                        

                                                                                                                                                                                                                                  

  Silbert 1995 \[[@B12]\]           1    74          ?                      Confluent        Dx                No                     No                         Death 6 weeks    Headache\                                       
                                                                                                                                                                                  Seizures                                        

                                                                                                                                                                                                                                  

  Fountain 1996 \[[@B13]\]          1    66          TGA                    Confluent        CP, Dx, Pn,       No                     Partial                    20 months        Encephalopathy\                                 
                                                                                                                                                                                  Headaches\                                      
                                                                                                                                                                                  Seizures                                        

                                                                                                                                                                                                                                  

  Fountain 1996 \[[@B13]\]          1    69          TGA                    Confluent        CP, Dx, Pn,       Partial                Partial                    Death 6 months   Encephalopathy\                                 Relapse
                                                                                                                                                                                  Headaches\                                      
                                                                                                                                                                                  Seizures                                        

                                                                                                                                                                                                                                  

  Ortiz 1996 \[[@B14]\]             1    68          PVI                    Mass             Dx, Pn            Yes                    Yes                        ?                Encephalopathy\                                 
                                                                                                                                                                                  Gait disturbance Headaches                      

                                                                                                                                                                                                                                  

  Masson 1998 \[[@B15]\]            1    64          PVI                    Confluent        CP, Pn            Yes                    No                         15 months        Encephalopathy\                                 
                                                                                                                                                                                  Headaches                                       

                                                                                                                                                                                                                                  

  Fountain 1999 \[[@B16]\]          1    71          PVI, TGA               Confluent        CP                Yes                    Yes                        22 months        Encephalopathy\                                 Relapse after stop CP
                                                                                                                                                                                  Gait disturbance\                               
                                                                                                                                                                                  Headaches                                       

                                                                                                                                                                                                                                  

  Streichenberger 1999 \[[@B17]\]   1    67          TGA                    Mass/Confluent   CS                Yes                    Yes                        Death 1 month    Headaches\                                      
                                                                                                                                                                                  Encephalopathy                                  

                                                                                                                                                                                                                                  

  Hoshi 2000 \[[@B18]\]             1    65          \- (after treatment)   Recurrent\       Pn                Yes                    NA                         6 months         Focal neurology                                 
                                                                            ICH                                                                                                                                                   

                                                                                                                                                                                                                                  

  Schwab 2003 \[[@B19]\]            1    74          PVI/TGA                Mass             Dx 1m, Pn         Yes                    ?                          12 months        Encephalopathy\                                 
                                                                                                                                                                                  Headaches\                                      
                                                                                                                                                                                  Seizures                                        

                                                                                                                                                                                                                                  

  Schwab 2003 \[[@B19]\]            1    70          PVI//TGA               Mass             Pn, CP            Partial                Yes                        18 months        Encephalopathy\                                 
                                                                                                                                                                                  Headaches\                                      
                                                                                                                                                                                  Seizures                                        

                                                                                                                                                                                                                                  

  Oh 2004 \[[@B20]\]                1    80          PVI                    Confluent        Dx, Pn            Yes                    Yes                        8 months         Encephalopathy\                                 1 patient with no therapy excluded
                                                                                                                                                                                  Focal Neurology\                                
                                                                                                                                                                                  Seizures                                        

                                                                                                                                                                                                                                  

  Oh 2004 \[[@B20]\]                1    77          TGA                    Confluent        Dx, Pn            Yes                    Yes                        6 weeks          Encephalopathy\                                 1 patient with no therapy excluded
                                                                                                                                                                                  Focal Neurology\                                
                                                                                                                                                                                  Seizures                                        

                                                                                                                                                                                                                                  

  Safriel 2004 \[[@B5]\]            1    49          TGA                    Mass             Dx, tap 6 weeks   Yes                    Partial                    9 months         Seizures                                        

                                                                                                                                                                                                                                  

  Scolding 2005 \[[@B21]\]          7    69\*        TGA                    Confluent        Pn, Dx, CP        43%                    ?                          58 months\*      Encephalopathy\                                 2 patients excluded because of mass resection as therapy
                                                                                                                                                                                  Focal Neurology\                                
                                                                                                                                                                                  Headaches\                                      
                                                                                                                                                                                  Seizures                                        

                                                                                                                                                                                                                                  

  Kinnecom 2007 \[[@B6]\]           12   63.2 ± 10   PVI                    Confluent        CS, CP            83%                    83%                        47 months\*      Encephalopathy Headache\                        25% relapse, 33% died
                                                                                                                                                                                  Seizures                                        

                                                                                                                                                                                                                                  

  McHugh 2007 \[[@B9]\]             1    80          PVI, TGA               Confluent        Pn                Yes                    Yes                        24 months        Encephalopathy\                                 
                                                                                                                                                                                  Focal Neurology\                                
                                                                                                                                                                                  Seizures                                        

                                                                                                                                                                                                                                  

  Machida 2008 \[[@B22]\]           1    69          PVI                    Confluent        Dx, Pn            Yes                    Yes                        12 months        Encephalopathy\                                 Relapsing/remitting
                                                                                                                                                                                  Focal neurology                                 

                                                                                                                                                                                                                                  

  Salvarini 2008 \[[@B23]\]         8    63          TGA                    Confluent        Pn, CP            75%                    100%                       24 months\*      Encephalopathy\                                 25% relapse, both after discontinuation of treatment
                                                                                                                                                                                  Focal Neurology\                                
                                                                                                                                                                                  Headaches                                       
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CS = corticosteroid (not otherwise specified), CP = Cyclophospamid, Dx = dexamethasone, Pn = prednisone, PVI = perivascular inflammation, TGA = transmural (non)-granulomatous angiitis

Encephalopathy is characterised as diffuse cognitive disturbances, somnolence and apathy, focal neurology is characterised as hemiparesis, hemihyesthesia, aphasia or hemianopsy.

\* calculated mean

Although publication bias, small study numbers and the possible self-limiting nature of the disease has to be taken into account, the quick response to immunosuppressive therapy and the tendency to relapse in drug-free periods suggest a beneficial effect of immunosuppressants. In general, patients with TGA did not benefit as much as patients with PVI \[68% vs 88%\]: possibly the vasculitic form gives rise to more ischemic lesions (reflected in the higher proportion of focal deficits in this group) than in PVI, in which there could be more vasogenic edema.

It is interesting that only CAA encephalopathy responds to corticosteroid treatment, in contrast to other Aβ-depositing disorders. A possible explanation could be that corticosteroids merely reduce cerebral vasogenic edema. However, in vitro research has shown that dexamethasone diminishes the pro-inflammatory and cytotoxic effects of Aβ in cerebrovascular smooth muscle cells in later stages of the inflammation process, although it does not affect initial Aβ deposition \[[@B23]\]. This suggests a direct effect upon the pathogenesis of acute inflammation in Aβ-disorders, as it is found in CAA encephalopathy. In any case, our review shows there is a possible role for the use of corticosteroids in patients with CAA encephalopathy.

Conclusions
===========

CAA encephalopathy is an increasingly recognized syndrome that is based upon a vasculitic or non-vasculitic inflammatory reaction to Aβ. Although the clinical and radiological symptoms are similar in both pathologic variants, immunosuppressive therapy appears to have a slightly less beneficial effect in the vasculitic subtype. Nevertheless, corticosteroid therapy seems to be an appropriate therapy for both. In an elderly patient with a subacute progressive encephalopathy with seizures, CAA-related encephalopathy has to be considered because of the major therapeutical implications.

Consent
=======

Written informed consent was obtained from the next of kin of the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests
===================

The authors declare that they have no competing interests.

Authors\' contributions
=======================

RPK participated in the design of the article, collected and analyzed the data and drafted the manuscript. ER, PE and PJN contributed to the analysis and interpretation of the data. MES and DT provided radiological and pathological data respectively. PJN conceived of the case report and coordinated the drafting of the manuscript. All authors read and approved the final manuscript.
